Literature DB >> 15798202

Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice.

Erinn B Rankin1, Debra F Higgins, Jacqueline A Walisser, Randall S Johnson, Christopher A Bradfield, Volker H Haase.   

Abstract

Patients with germ line mutations in the VHL tumor suppressor gene are predisposed to the development of highly vascularized tumors within multiple tissues. Loss of pVHL results in constitutive activation of the transcription factors HIF-1 and HIF-2, whose relative contributions to the pathogenesis of the VHL phenotype have yet to be defined. In order to examine the role of HIF in von Hippel-Lindau (VHL)-associated vascular tumorigenesis, we utilized Cre-loxP-mediated recombination to inactivate hypoxia-inducible factor-1alpha (Hif-1alpha) and arylhydrocarbon receptor nuclear translocator (Arnt) genes in a VHL mouse model of cavernous liver hemangiomas and polycythemia. Deletion of Hif-1alpha did not affect the development of vascular tumors and polycythemia, nor did it suppress the increased expression of vascular endothelial growth factor (Vegf) and erythropoietin (Epo). In contrast, phosphoglycerokinase (Pgk) expression was substantially decreased, providing evidence for target gene-dependent functional redundancy between different Hif transcription factors. Inactivation of Arnt completely suppressed the development of hemangiomas, polycythemia, and Hif-induced gene expression. Here, we demonstrate genetically that the development of VHL-associated vascular tumors in the liver depends on functional ARNT. Furthermore, we provide evidence that individual HIF transcription factors may play distinct roles in the development of specific VHL disease manifestations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15798202      PMCID: PMC1069599          DOI: 10.1128/MCB.25.8.3163-3172.2005

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  65 in total

1.  Hepatic hemangioblastoma: an unusual presentation of von Hippel-Lindau disease.

Authors:  K Hayasaka; Y Tanaka; T Satoh; H Mutoh
Journal:  J Comput Assist Tomogr       Date:  1999 Jul-Aug       Impact factor: 1.826

2.  Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex.

Authors:  Mindy A Maynard; Heng Qi; Jacky Chung; Eric H L Lee; Yukihiro Kondo; Shuntaro Hara; Ronald C Conaway; Joan W Conaway; Michael Ohh
Journal:  J Biol Chem       Date:  2003-01-21       Impact factor: 5.157

3.  Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia.

Authors:  Heidi M Sowter; Raju R Raval; John W Moore; Peter J Ratcliffe; Adrian L Harris
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

Review 4.  Molecular basis of the VHL hereditary cancer syndrome.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

5.  Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene.

Authors:  Wenbin Ma; Lino Tessarollo; Seung-Beom Hong; Masaya Baba; Eileen Southon; Timothy C Back; Sally Spence; Corrinne G Lobe; Nirmala Sharma; Gregory W Maher; Svetlana Pack; Alexander O Vortmeyer; Chuanfa Guo; Berton Zbar; Laura S Schmidt
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

6.  Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs.

Authors:  Michael S Wiesener; Jan Steffen Jürgensen; Christian Rosenberger; Charlotte K Scholze; Jan H Hörstrup; Christina Warnecke; Stefano Mandriota; Ingo Bechmann; Ulrich A Frei; Christopher W Pugh; Peter J Ratcliffe; Sebastian Bachmann; Patrick H Maxwell; Kai-Uwe Eckardt
Journal:  FASEB J       Date:  2002-12-17       Impact factor: 5.191

7.  Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.

Authors:  Peter Staller; Jitka Sulitkova; Joanna Lisztwan; Holger Moch; Edward J Oakeley; Wilhelm Krek
Journal:  Nature       Date:  2003-09-18       Impact factor: 49.962

8.  Transgenic mice overexpressing erythropoietin adapt to excessive erythrocytosis by regulating blood viscosity.

Authors:  Johannes Vogel; Isabel Kiessling; Katja Heinicke; Thomas Stallmach; Pete Ossent; Olga Vogel; Michael Aulmann; Thomas Frietsch; Holger Schmid-Schönbein; Wolfgang Kuschinsky; Max Gassmann
Journal:  Blood       Date:  2003-05-15       Impact factor: 22.113

9.  Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL.

Authors:  Alexander Hergovich; Joanna Lisztwan; Robert Barry; Pia Ballschmieter; Wilhelm Krek
Journal:  Nat Cell Biol       Date:  2003-01       Impact factor: 28.824

10.  Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2alpha.

Authors:  I Flamme; M Krieg; K H Plate
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

View more
  73 in total

1.  Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo.

Authors:  William Y Kim; Michal Safran; Marshall R M Buckley; Benjamin L Ebert; Jonathan Glickman; Marcus Bosenberg; Meredith Regan; William G Kaelin
Journal:  EMBO J       Date:  2006-09-14       Impact factor: 11.598

2.  The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo.

Authors:  Qin Yan; Steven Bartz; Mao Mao; Lianjie Li; William G Kaelin
Journal:  Mol Cell Biol       Date:  2007-01-12       Impact factor: 4.272

3.  Vascular biology and pathobiology of the liver: Report of a single-topic symposium.

Authors:  Yasuko Iwakiri; Matthew Grisham; Vijay Shah
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

4.  Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia.

Authors:  Pinelopi P Kapitsinou; Qingdu Liu; Travis L Unger; Jennifer Rha; Olena Davidoff; Brian Keith; Jonathan A Epstein; Sheri L Moores; Connie L Erickson-Miller; Volker H Haase
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

5.  The RNA-binding protein, ZC3H14, is required for proper poly(A) tail length control, expression of synaptic proteins, and brain function in mice.

Authors:  Jennifer Rha; Stephanie K Jones; Jonathan Fidler; Ayan Banerjee; Sara W Leung; Kevin J Morris; Jennifer C Wong; George Andrew S Inglis; Lindsey Shapiro; Qiudong Deng; Alicia A Cutler; Adam M Hanif; Machelle T Pardue; Ashleigh Schaffer; Nicholas T Seyfried; Kenneth H Moberg; Gary J Bassell; Andrew Escayg; Paul S García; Anita H Corbett
Journal:  Hum Mol Genet       Date:  2017-10-01       Impact factor: 6.150

6.  von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis.

Authors:  Michele M Hickey; Jennifer C Lam; Natalie A Bezman; W Kimryn Rathmell; M Celeste Simon
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

7.  Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis.

Authors:  Kuniko Kimura; Masayuki Iwano; Debra F Higgins; Yukinari Yamaguchi; Kimihiko Nakatani; Koji Harada; Atsushi Kubo; Yasuhiro Akai; Erinn B Rankin; Eric G Neilson; Volker H Haase; Yoshihiko Saito
Journal:  Am J Physiol Renal Physiol       Date:  2008-07-30

Review 8.  Regulation of angiogenesis by oxygen sensing mechanisms.

Authors:  Guo-Hua Fong
Journal:  J Mol Med (Berl)       Date:  2009-03-14       Impact factor: 4.599

Review 9.  Advances in understanding the mechanisms of erythropoiesis in homeostasis and disease.

Authors:  Raymond Liang; Saghi Ghaffari
Journal:  Br J Haematol       Date:  2016-07-21       Impact factor: 6.998

Review 10.  Neuronal apoptosis by prolyl hydroxylation: implication in nervous system tumours and the Warburg conundrum.

Authors:  Susanne Schlisio
Journal:  J Cell Mol Med       Date:  2009-08-19       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.